INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

• Published in: Contemporary clinical trials communications 2023-12, Vol.36, p.101211-101211, Article 101211
• Main Authors: Weinberg, Ethan, Rahematpura, Suditi, Gonzalez, Stevan A., Izzy, Manhal J., Simonetto, Douglas A., Frederick, R. Todd, Rubin, Raymond A., Ikahihifo-Bender, Jade, Harte, Maggie, Kim-Lee, Grace, Witkiewicz, Sherry, Tobin, William, Jamil, Khurram, Fricker, Zachary, Reddy, K. Rajender
• Format: Article
• Language: English
• Subjects: Ascites; Decompensated cirrhosis; Hepatorenal syndrome; Liver transplant; Portal hypertension
• ISSN: 2451-8654; 2451-8654
• DOI: 10.1016/j.conctc.2023.101211

Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of terlipressin, however, is hindered by the paucity of local data on the optimal patient population and administration mode, as well as the effect on transplant priority. The INFUSE study is designed to evaluate the use of continuous terlipressin infusion among transplant candidates with advanced liver disease and HRS-AKI. Fifty prospective patients with HRS-AKI will receive a single bolus of terlipressin 0.5 mg followed by continuous infusions of terlipressin from 2 to 8 mg/day for up to 14 days. The cohort will be enriched with those listed, in evaluation, or eligible for liver transplantation, while those with ACLF grade 3, MELD ≥35, and serum creatinine >5.0 mg/dL will be excluded. Fifty patients who received midodrine plus octreotide or norepinephrine for HRS-AKI will serve as a retrospective comparator cohort. The INFUSE study aims to assess the safety and efficacy of continuous terlipressin infusion among largely transplant-eligible patients with HRS-AKI, and to provide US-based data on transplant outcomes. This novel study design simultaneously mitigates terlipressin adverse events while providing renal benefits to patients, thus addressing the unmet medical need of those with HRS-AKI who have limited treatment options and are awaiting liver transplantation in the US.